Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by palinc2000on Jul 08, 2022 12:40pm
137 Views
Post# 34811276

RE:Another update

RE:Another updateOuf Juniper!You might not feel it but I am so with you and feel your pain...You have done all that is humanely possible and that is a very important element in your healing process...You are a good man ! The way you care for her means that she is also an extraordinary wife 
May God Bless you both

juniper88 wrote: My wife has been move to to Princess Margaret palliative care so that she may be comfortable in whatever time she has left. I have know many of you for many years and I am appreciative of all the good thoughts and prayers. It is a very difficult time for our family, but still I feel the pull to let you all know what I have seen from the phase 1 trial my wife was on. I am writing this post from my cell phone, so everything appears in one paragraph. First, I will disclose that I sold about 10k TH shares because i need the money to pay for the funeral, burial, etc. The second disclosure is that my wife was one the TH1902 trial. We got CT scan reports back earlier this week that showed both regression and progression of tumors. I know for sure that TH1901 works. We can see that from the tumors that regressed and the substantial lowering in my wife's tumor marker. These trials are about research, getting more information. Efficacy would be great but it is complicated. On July 1st I noticed that my wife's eye became yellow again. A few days later she had deteriorated and I toke her to the ER, where they rushed her inside. They did the CT scans and found abscesses in the liver and that the bile duct stent had become blocked. They told me that she had a severe bacterial infection likely originating from the stent, but it also could just be the cancer. We were offered a procedure to replace the stent but we declined, as it would ultimately not change the outcome. The question about the trial I have is why did only some tumors regress? Was it because those tumors did not have SORT1? Or was docetaxel not effective against those? My wife got the 300mg/m2 dosage. She lost almost now hair which tells us that there was very little free docetaxel in her blood. That would also tell us that the tumor regression came because TH1902 rather than free docetaxel. Ovarian cancer is very heterogeneous. So it is very possible that the tumors that progressed were a cancer line resistant in some other way. A more powerful bomb would help. On the other hand if those tumors didn't over express SORT1 then the TH1901 simply wouldn't work against those tumors. Also about the trial, the weekly blood work is onerous on late stage cancer patients. It might even keep some patients out of the trial. But from what I know, recruitment is happening fast.


<< Previous
Bullboard Posts
Next >>